Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Syndax Pharmaceuticals Inc is a biotechnology business based in the US. Syndax Pharmaceuticals shares (SNDX) are listed on the NASDAQ and all prices are listed in US Dollars. Syndax Pharmaceuticals employs 59 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $19.07 |
|---|---|
| 52-week range | $13.27 - $22.71 |
| 50-day moving average | $16.17 |
| 200-day moving average | $17.43 |
| Wall St. target price | $31.29 |
| PE ratio | 69.6715 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.27 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.07 from 2022-07-01
| 1 week (2022-06-24) | -0.31% |
|---|---|
| 1 month (2022-06-02) | 14.88% |
| 3 months (2022-04-01) | 8.23% |
| 6 months (2021-12-31) | -12.88% |
| 1 year (2021-07-02) | 8.41% |
|---|---|
| 2 years (2020-07-02) | 30.80% |
| 3 years (2019-07-02) | 111.18% |
| 5 years (2017-06-30) | 36.51% |
Valuing Syndax Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Syndax Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Syndax Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 70x. In other words, Syndax Pharmaceuticals shares trade at around 70x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Syndax Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.6 million.
The EBITDA is a measure of a Syndax Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $139.3 million |
|---|---|
| Operating margin TTM | 11.86% |
| Gross profit TTM | $139.7 million |
| Return on assets TTM | 2.94% |
| Return on equity TTM | 5.14% |
| Profit margin | 11.11% |
| Book value | $6.81 |
| Market capitalisation | $1.1 billion |
TTM: trailing 12 months
We're not expecting Syndax Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Syndax Pharmaceuticals's shares have ranged in value from as little as $13.27 up to $22.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syndax Pharmaceuticals's is 1.5304. This would suggest that Syndax Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Syndax Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co. , Ltd. Syndax Pharmaceuticals, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.